Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN   3:59:59 PM EDT
138.74
-1.16 (-0.83%)
4:00:00 PM EDT: $138.99 +0.25 (+0.18%)
Products, Earnings Announcements

Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT

Published: 10/05/2021 11:39 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Biohaven Announces Preliminary 3q2021 Net Product Revenue for Nurtec Odt, the First and Only Migraine Medication for Both Acute and Preventive Treatment.
Biohaven Pharmaceutical - Nurtec Odt Achieved Preliminary Net Product Revenue of Approximately $136 Million for Q3 of 2021.
Biohaven Pharmaceutical - Launch to Date Net Product Revenue for Nurtec Odt is Approximately $336 Million.
Revenue is expected to be $110.3 Million
Adjusted EPS is expected to be -$2.47

Next Quarter Revenue Guidance is expected to be $143.14 Million
Next Quarter EPS Guidance is expected to be -$2.14

More details on our Analysts Page.